EMA — authorised 7 September 1999
- Marketing authorisation holder: NovoRapid
- Status: approved
EMA authorised Novolog on 7 September 1999
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 7 September 1999.
NovoRapid holds the EU marketing authorisation.